Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.17
RTIX's Cash to Debt is ranked lower than
88% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.22 vs. RTIX: 0.17 )
Ranked among companies with meaningful Cash to Debt only.
RTIX' s Cash to Debt Range Over the Past 10 Years
Min: 0.09  Med: 1.92 Max: N/A
Current: 0.17
Equity to Asset 0.48
RTIX's Equity to Asset is ranked lower than
69% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. RTIX: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
RTIX' s Equity to Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.75 Max: 0.9
Current: 0.48
0.3
0.9
Interest Coverage 8.76
RTIX's Interest Coverage is ranked lower than
79% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 76.81 vs. RTIX: 8.76 )
Ranked among companies with meaningful Interest Coverage only.
RTIX' s Interest Coverage Range Over the Past 10 Years
Min: 4.15  Med: 16.58 Max: N/A
Current: 8.76
F-Score: 4
Z-Score: 1.01
M-Score: -2.62
WACC vs ROIC
8.92%
3.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 5.05
RTIX's Operating margin (%) is ranked higher than
56% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. RTIX: 5.05 )
Ranked among companies with meaningful Operating margin (%) only.
RTIX' s Operating margin (%) Range Over the Past 10 Years
Min: -76.65  Med: -0.3 Max: 8.72
Current: 5.05
-76.65
8.72
Net-margin (%) 2.80
RTIX's Net-margin (%) is ranked higher than
54% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. RTIX: 2.80 )
Ranked among companies with meaningful Net-margin (%) only.
RTIX' s Net-margin (%) Range Over the Past 10 Years
Min: -77.87  Med: -0.6 Max: 5.28
Current: 2.8
-77.87
5.28
ROE (%) 2.43
RTIX's ROE (%) is ranked higher than
52% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. RTIX: 2.43 )
Ranked among companies with meaningful ROE (%) only.
RTIX' s ROE (%) Range Over the Past 10 Years
Min: -57.28  Med: -1.07 Max: 6.65
Current: 2.43
-57.28
6.65
ROA (%) 2.05
RTIX's ROA (%) is ranked higher than
57% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: -0.43 vs. RTIX: 2.05 )
Ranked among companies with meaningful ROA (%) only.
RTIX' s ROA (%) Range Over the Past 10 Years
Min: -44.6  Med: -0.43 Max: 3.93
Current: 2.05
-44.6
3.93
ROC (Joel Greenblatt) (%) 6.55
RTIX's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 4.23 vs. RTIX: 6.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RTIX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -91.98  Med: 0.42 Max: 12.01
Current: 6.55
-91.98
12.01
Revenue Growth (3Y)(%) 14.90
RTIX's Revenue Growth (3Y)(%) is ranked higher than
82% of the 234 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. RTIX: 14.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RTIX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -22.6  Med: 1.7 Max: 14.9
Current: 14.9
-22.6
14.9
EBITDA Growth (3Y)(%) 24.60
RTIX's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. RTIX: 24.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RTIX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -49.1  Med: -1.4 Max: 127.4
Current: 24.6
-49.1
127.4
EPS Growth (3Y)(%) 10.10
RTIX's EPS Growth (3Y)(%) is ranked higher than
61% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. RTIX: 10.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RTIX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.6  Med: 10.1 Max: 223.1
Current: 10.1
-47.6
223.1
» RTIX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

RTIX Guru Trades in Q3 2015

Chuck Royce 1,190,774 sh (-6.15%)
Jim Simons 249,700 sh (-18.24%)
» More
Q4 2015

RTIX Guru Trades in Q4 2015

Chuck Royce 1,558,774 sh (+30.90%)
Jim Simons 257,200 sh (+3.00%)
» More
Q1 2016

RTIX Guru Trades in Q1 2016

Jim Simons 326,700 sh (+27.02%)
Chuck Royce 1,626,234 sh (+4.33%)
» More
Q2 2016

RTIX Guru Trades in Q2 2016

Jim Simons 388,500 sh (+18.92%)
Chuck Royce 1,003,055 sh (-38.32%)
» More
» Details

Insider Trades

Latest Guru Trades with RTIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NAS:IRMD, NAS:PAVM, OTCPK:VICA, NAS:TNDM, NAS:ELOS, AMEX:CVRS, NAS:IRIX, NAS:ACRX, NAS:EYES, NAS:CUTR, NAS:FONR, OTCPK:JLFNF, NAS:AXGN, NAS:VRAY, NAS:SPNE, NAS:DRAD, NAS:VIVE, NYSE:GI, OTCPK:ARTH, OTCPK:TITXF » details
Traded in other countries:RT2.Germany,
RTI Surgical Inc is a surgical implant company. It processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera, dermal tissue and bovine and porcine animal tissue..

RTI Surgical Inc, formerly RTI Biologics, Inc., was incorporated in 1997 in Florida as a wholly-owned subsidiary of the University of Florida Tissue Bank. The Company process donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing proprietary BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes and manufacture metal and synthetic implants for distribution to hospitals and surgeons. The Company process tissue at two facilities in Alachua, Florida and one facility in Neunkirchen, Germany, and manufacture metal and synthetic implants in Marquette, Michigan and Greenville, North Carolina. The Company distributes its implants and services in all 50 states and in over 45 countries. Its lines of business are comprised primarily of six categories: spine, sports medicine, surgical specialties, bone graft substitutes and general orthopedic, dental and ortho fixation. It has developed and utilized in the United States the patented BioCleanse tissue sterilization process, which is an automated, pharmaceutical grade chemical sterilization process for musculoskeletal bone and certain soft tissue. The TUTOPLAST tissue sterilization process utilizes solvent dehydration and chemical inactivation to remove blood, lipids and extraneous materials, and inactivate viruses and break down RNA and DNA into fragments not capable of replication and disease transmission while preserving the biological and mechanical properties. DBM-based pastes and putties are sterilized through the CANCELLE SP process, which is designed to preserve protein activity. The Company's competitors in the conventional allograft market include the Musculoskeletal Transplant Foundation ("MTF"), AlloSource, LifeCell, Inc., a subsidiary of Kinetic Concepts Inc. and LifeNet. Among its competitors in precision machined allograft are MTF, LifeNet and AlloSource. Other companies who process and distribute allograft pastes include Medtronic, AlloSource, Integra, Wright and MTF. Companies who process and distribute xenograft tissue include Synovis, LifeCell, Cook Surgical and Medtronic. The Company considers its competitors in the metal and synthetic markets to include Alphatec, Globus Medical, Inc. (Globus), NuVasive, Inc. (NuVasive) and Orthofix. The Company is subject to federal, state and foreign laws and regulations.

Ratios

vs
industry
vs
history
P/E(ttm) 36.01
RTIX's P/E(ttm) is ranked lower than
64% of the 163 Companies
in the Global Medical Devices industry.

( Industry Median: 28.46 vs. RTIX: 36.01 )
Ranked among companies with meaningful P/E(ttm) only.
RTIX' s P/E(ttm) Range Over the Past 10 Years
Min: 14.38  Med: 28.82 Max: 68.21
Current: 36.01
14.38
68.21
PE(NRI) 36.01
RTIX's PE(NRI) is ranked lower than
64% of the 164 Companies
in the Global Medical Devices industry.

( Industry Median: 29.43 vs. RTIX: 36.01 )
Ranked among companies with meaningful PE(NRI) only.
RTIX' s PE(NRI) Range Over the Past 10 Years
Min: 14.38  Med: 28.85 Max: 72
Current: 36.01
14.38
72
P/B 1.01
RTIX's P/B is ranked higher than
87% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.95 vs. RTIX: 1.01 )
Ranked among companies with meaningful P/B only.
RTIX' s P/B Range Over the Past 10 Years
Min: 0.27  Med: 1.29 Max: 3.17
Current: 1.01
0.27
3.17
P/S 0.70
RTIX's P/S is ranked higher than
87% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 3.22 vs. RTIX: 0.70 )
Ranked among companies with meaningful P/S only.
RTIX' s P/S Range Over the Past 10 Years
Min: 0.62  Med: 1.24 Max: 4.34
Current: 0.7
0.62
4.34
POCF 12.16
RTIX's POCF is ranked higher than
70% of the 131 Companies
in the Global Medical Devices industry.

( Industry Median: 21.00 vs. RTIX: 12.16 )
Ranked among companies with meaningful POCF only.
RTIX' s POCF Range Over the Past 10 Years
Min: 3.57  Med: 28.96 Max: 924
Current: 12.16
3.57
924
EV-to-EBIT 18.06
RTIX's EV-to-EBIT is ranked higher than
59% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 22.20 vs. RTIX: 18.06 )
Ranked among companies with meaningful EV-to-EBIT only.
RTIX' s EV-to-EBIT Range Over the Past 10 Years
Min: -341.4  Med: -1 Max: 542.1
Current: 18.06
-341.4
542.1
EV-to-EBITDA 8.20
RTIX's EV-to-EBITDA is ranked higher than
80% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: 17.64 vs. RTIX: 8.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
RTIX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -123.4  Med: 7.4 Max: 484.2
Current: 8.2
-123.4
484.2
Current Ratio 3.30
RTIX's Current Ratio is ranked higher than
63% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.50 vs. RTIX: 3.30 )
Ranked among companies with meaningful Current Ratio only.
RTIX' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 3.6 Max: 5.91
Current: 3.3
1
5.91
Quick Ratio 1.14
RTIX's Quick Ratio is ranked lower than
75% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. RTIX: 1.14 )
Ranked among companies with meaningful Quick Ratio only.
RTIX' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 1.57 Max: 3.07
Current: 1.14
0.49
3.07
Days Inventory 330.42
RTIX's Days Inventory is ranked lower than
88% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 133.25 vs. RTIX: 330.42 )
Ranked among companies with meaningful Days Inventory only.
RTIX' s Days Inventory Range Over the Past 10 Years
Min: 248.06  Med: 305.71 Max: 366.78
Current: 330.42
248.06
366.78
Days Sales Outstanding 48.99
RTIX's Days Sales Outstanding is ranked higher than
79% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 68.07 vs. RTIX: 48.99 )
Ranked among companies with meaningful Days Sales Outstanding only.
RTIX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.51  Med: 45.32 Max: 61.08
Current: 48.99
36.51
61.08
Days Payable 71.17
RTIX's Days Payable is ranked higher than
57% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 58.34 vs. RTIX: 71.17 )
Ranked among companies with meaningful Days Payable only.
RTIX' s Days Payable Range Over the Past 10 Years
Min: 44.15  Med: 54.7 Max: 83.22
Current: 71.17
44.15
83.22

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.10
RTIX's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. RTIX: -1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RTIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.4  Med: -4.05 Max: -0.8
Current: -1.1
-22.4
-0.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 1.88
RTIX's Price/Tangible Book is ranked higher than
80% of the 260 Companies
in the Global Medical Devices industry.

( Industry Median: 4.37 vs. RTIX: 1.88 )
Ranked among companies with meaningful Price/Tangible Book only.
RTIX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.98  Med: 2.5 Max: 5.93
Current: 1.88
0.98
5.93
Price/Projected FCF 1.18
RTIX's Price/Projected FCF is ranked higher than
78% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 2.14 vs. RTIX: 1.18 )
Ranked among companies with meaningful Price/Projected FCF only.
RTIX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.76  Med: 1.4 Max: 91.43
Current: 1.18
0.76
91.43
Price/Median PS Value 0.55
RTIX's Price/Median PS Value is ranked higher than
83% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. RTIX: 0.55 )
Ranked among companies with meaningful Price/Median PS Value only.
RTIX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.55  Med: 1.17 Max: 3.33
Current: 0.55
0.55
3.33
Price/Graham Number 1.73
RTIX's Price/Graham Number is ranked higher than
58% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. RTIX: 1.73 )
Ranked among companies with meaningful Price/Graham Number only.
RTIX' s Price/Graham Number Range Over the Past 10 Years
Min: 1  Med: 2.03 Max: 4.04
Current: 1.73
1
4.04
Earnings Yield (Greenblatt) (%) 5.60
RTIX's Earnings Yield (Greenblatt) (%) is ranked higher than
79% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. RTIX: 5.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RTIX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 5.4 Max: 10.1
Current: 5.6
0.2
10.1

More Statistics

Revenue (TTM) (Mil) $277.6
EPS (TTM) $ 0.09
Beta1.39
Short Percentage of Float2.83%
52-Week Range $2.81 - 6.55
Shares Outstanding (Mil)58.42

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 287 305
EPS ($) 0.20 0.29
EPS w/o NRI ($) 0.20 0.29
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for RTIX

Headlines

Articles On GuruFocus.com
Regeneration Technologies Inc. Reports Operating Results (10-Q) Nov 08 2010 
Weekly CFO Buys Highlight: Bank Mutual Corp., Heelys Inc., GenMark Diagnostics Inc., Regeneration Te Sep 19 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 
Regeneration Technologies Inc. Reports Operating Results (10-Q) Aug 09 2010 
Regeneration Technologies Inc. Reports Operating Results (10-Q) May 05 2010 
Regeneration Technologies Inc. Reports Operating Results (10-Q) Nov 02 2009 
Regeneration Technologies Inc. Reports Operating Results (10-Q) Aug 04 2009 
Regeneration Technologies Inc. Reports Operating Results (10-Q) May 02 2009 

More From Other Websites
RTI SURGICAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Aug 16 2016
RTI Surgical® Announces CEO Brian Hutchison to Retire Aug 15 2016
RTI Surgical Announces CEO Brian Hutchison to Retire Aug 15 2016
RTI SURGICAL, INC. Financials Aug 12 2016
ETF’s with exposure to RTI Surgical, Inc. : August 8, 2016 Aug 08 2016
RTI Surgical, Inc. :RTIX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 Aug 05 2016
RTI SURGICAL, INC. Files SEC form 10-Q, Quarterly Report Aug 04 2016
Krensavage Poses Questions to RTI Surgical in Open Letter Jul 28 2016
RTI Surgical downgraded by Craig Hallum Jul 28 2016
Edited Transcript of RTIX earnings conference call or presentation 27-Jul-16 12:30pm GMT Jul 27 2016
RTI Surgical Inc Earnings Call scheduled for 8:30 am ET today Jul 27 2016
RTI Surgical reports 2Q loss Jul 27 2016
RTI Surgical reports 2Q loss Jul 27 2016
RTI SURGICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 27 2016
RTI Surgical® Announces 2016 Second Quarter Results Jul 27 2016
RTI Surgical® Announces 2016 Second Quarter Results Jul 27 2016
Q2 2016 RTI Surgical Inc Earnings Release - Before Market Open Jul 27 2016
Look at Jul 27 Medical Instrument Earnings: HOLX, VAR & More Jul 26 2016
RTI Surgical® Continues to Advance Science Behind Allograft Implantation Jul 25 2016
RTI Surgical® Continues to Advance Science Behind Allograft Implantation Jul 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)